NEOK Bio vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.
About
NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.